10. Neurohormones versus placebo: adverse effects data that could not be used in the meta‐analysis.
Name of study | Short‐/medium‐/long‐term outcomes | Group 1 sample size | Group 1 sample size | Group 1 results Mean (standard deviation) | Group 2 results Mean (standard deviation) | Other data | Notes |
Sikich 2013 | Short‐term oxytocin (max 24 IU children 3‐10 years or max 32 IU children 11‐17 years) adverse effects (metabolic) | 11 | 13 | 0.64 (1.95) | 1.09 (1.14) | ‐ | Skewed |